{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:45:52Z","timestamp":1793029552692,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.03.101","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:18Z","timestamp":1495670418000},"page":"5471-5480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant"],"prefix":"10.1016","volume":"35","author":[{"given":"Vishal M.","family":"Toprani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Russell","family":"Middaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Volkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.03.101_b0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2017.03.101_b0010","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2017.03.101_b0015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2017.03.101_b0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.smim.2013.05.007","article-title":"Vaccine adjuvant formulations: a pharmaceutical perspective","volume":"25","author":"Brito","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2017.03.101_b0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1208\/s12248-011-9261-1","article-title":"A rational, systematic approach for the development of vaccine formulations","volume":"13","author":"Morefield","year":"2011","journal-title":"The AAPS J"},{"issue":"Supplement 2","key":"10.1016\/j.vaccine.2017.03.101_b0030","doi-asserted-by":"crossref","first-page":"B14","DOI":"10.1016\/j.vaccine.2015.01.088","article-title":"New generation adjuvants \u2013 from empiricism to rational design","volume":"33","author":"O\u2019Hagan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.101_b0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14760584.2014.907528","article-title":"Physicochemical and functional characterization of vaccine antigens and adjuvants","volume":"13","author":"Dey","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.03.101_b0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrd1695","article-title":"Protein drug stability: a formulation challenge","volume":"4","author":"Frokjaer","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2017.03.101_b0045","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/14760584.2014.923761","article-title":"Tools and approaches to ensure quality of vaccines throughout the cold chain","volume":"13","author":"Kartoglu","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.03.101_b0050","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/bit.23155","article-title":"Aggregates in monoclonal antibody manufacturing processes","volume":"108","author":"V\u00e1zquez-Rey","year":"2011","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.03.101_b0055","series-title":"Aggregation of therapeutic proteins","author":"Wang","year":"2010"},{"key":"10.1016\/j.vaccine.2017.03.101_b0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2017.03.101_b0065","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.addr.2011.07.006","article-title":"Protein\u2013excipient interactions: mechanisms and biophysical characterization applied to protein formulation development","volume":"63","author":"Kamerzell","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2017.03.101_b0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1461-5347(00)00248-0","article-title":"The formulation of biopharmaceutical products","volume":"3","author":"Parkins","year":"2000","journal-title":"Pharm Sci Technol Today"},{"key":"10.1016\/j.vaccine.2017.03.101_b0075","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.addr.2011.06.011","article-title":"Interactions of formulation excipients with proteins in solution and in the dried state","volume":"63","author":"Ohtake","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2017.03.101_b0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejpb.2006.09.009","article-title":"High throughput screening of protein formulation stability: practical considerations","volume":"65","author":"Capelle","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2017.03.101_b0085","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CVI.00538-10","article-title":"Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant","volume":"18","author":"Norton","year":"2011","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.03.101_b0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11095-006-9131-1","article-title":"Sorbitol crystallization can lead to protein aggregation in frozen protein formulations","volume":"24","author":"Piedmonte","year":"2007","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2017.03.101_b0095","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/jps.24141","article-title":"Sorbitol crystallization-induced aggregation in frozen mAb formulations","volume":"104","author":"Piedmonte","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.03.101_b0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2009.05.008","article-title":"Impact of bulking agents on the stability of a lyophilized monoclonal antibody","volume":"38","author":"Meyer","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.03.101_b0105","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/BF02980247","article-title":"Effects of sugar additives on protein stability of recombinant human serum albumin during lyophilization and storage","volume":"30","author":"Han","year":"2007","journal-title":"Arch Pharmacal Res"},{"key":"10.1016\/j.vaccine.2017.03.101_b0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/jf9804387","article-title":"Modification of bovine \u03b2-lactoglobulin by glycation in a powdered state or in an aqueous solution: effect on association behavior and protein conformation","volume":"47","author":"Morgan","year":"1999","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.vaccine.2017.03.101_b0115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejpb.2008.04.021","article-title":"Glycation during storage and administration of monoclonal antibody formulations","volume":"70","author":"Fischer","year":"2008","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2017.03.101_b0120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/erv.09.20","article-title":"Opportunities and challenges of developing thermostable vaccines","volume":"8","author":"Chen","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.03.101_b0125","unstructured":"Prevention CfDCa. Vaccine excipient & media summary. Excipients included in U.S. vaccines, by vaccine http:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/appendices\/B\/excipient-table-2.pdf [accessed 23.07.16]."},{"key":"10.1016\/j.vaccine.2017.03.101_b0130","doi-asserted-by":"crossref","first-page":"11917","DOI":"10.1073\/pnas.94.22.11917","article-title":"Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state","volume":"94","author":"Kendrick","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.03.101_b0135","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1023\/A:1012180707283","article-title":"Rational design of stable lyophilized protein formulations: some practical advice","volume":"14","author":"Carpenter","year":"1997","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2017.03.101_b0140","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1016\/S0021-9258(19)68947-7","article-title":"The stabilization of proteins by sucrose","volume":"256","author":"Lee","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2017.03.101_b0145","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1110\/ps.0242603","article-title":"Effects of sucrose on conformational equilibria and fluctuations within the native-state ensemble of proteins","volume":"12","author":"Kim","year":"2003","journal-title":"Protein Sci: A Publ Protein Soc"},{"key":"10.1016\/j.vaccine.2017.03.101_b0150","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1021\/bi00483a001","article-title":"Dominant forces in protein folding","volume":"29","author":"Dill","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.vaccine.2017.03.101_b0155","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1110\/ps.0235703","article-title":"Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor","volume":"12","author":"Chi","year":"2003","journal-title":"Protein Sci"},{"key":"10.1016\/j.vaccine.2017.03.101_b0160","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1023\/A:1025771421906","article-title":"Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation","volume":"20","author":"Chi","year":"2003","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2017.03.101_b0165","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/(SICI)1097-0290(19980805)59:3<281::AID-BIT3>3.0.CO;2-7","article-title":"II. Electrostatic effect in the aggregation of heat-denatured RNase A and implications for protein additive design","volume":"59","author":"Tsai","year":"1998","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.03.101_b0170","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1021\/js980126i","article-title":"Effect of tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII","volume":"87","author":"Krielgaard","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.03.101_b0175","series-title":"Protein aggregation and particle formation: effects of formulation, interfaces, and drug product manufacturing operations","first-page":"301","author":"Mahler","year":"2010"},{"key":"10.1016\/j.vaccine.2017.03.101_b0180","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.addr.2011.06.015","article-title":"Molecular origins of surfactant-mediated stabilization of protein drugs","volume":"63","author":"Lee","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2017.03.101_b0185","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/jps.21190","article-title":"Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways","volume":"97","author":"Kerwin","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.03.101_b0190","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/js960080y","article-title":"Surface-induced denaturation of proteins during freezing and its inhibition by surfactants","volume":"85","author":"Chang","year":"1996","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.03.101_b0195","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/bit.260480511","article-title":"Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization","volume":"48","author":"Li","year":"1995","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.03.101_b0200","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/js970143s","article-title":"Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2","volume":"86","author":"Lam","year":"1997","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.03.101_b0205","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11095-010-0343-z","article-title":"Frozen state storage instability of a monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding","volume":"28","author":"Singh","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2017.03.101_b0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/10409239009090612","volume":"25","author":"Cold Denaturation of Protein","year":"1990","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.vaccine.2017.03.101_b0215","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1098\/rstb.1990.0030","article-title":"Protein structure and function at low temperatures [and discussion]","volume":"326","author":"Jaenicke","year":"1990","journal-title":"Philos Trans R Soc B: Biol Sci"},{"key":"10.1016\/j.vaccine.2017.03.101_b0220","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/jps.21433","article-title":"Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine","volume":"98","author":"Clausi","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.03.101_b0225","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/jps.22815","article-title":"Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants","volume":"101","author":"Salnikova","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.03.101_b0230","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/10837450701481157","article-title":"Protein stability during freezing: separation of stresses and mechanisms of protein stabilization","volume":"12","author":"Bhatnagar","year":"2007","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.vaccine.2017.03.101_b0235","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.vaccine.2017.03.101_b0240","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2008.04.036","article-title":"Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens","volume":"364","author":"Perrie","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2017.03.101_b0245","series-title":"Molecule and manufacturability assessment leading to robust commercial formulation for therapeutic proteins","author":"Kolhe","year":"2013"},{"key":"10.1016\/j.vaccine.2017.03.101_b0250","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1016\/j.vaccine.2016.02.076","article-title":"Status of vaccine research and development for enterotoxigenic Escherichia coli","volume":"34","author":"Bourgeois","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17304759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17304759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T18:39:29Z","timestamp":1692815969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17304759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":50,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17304759"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.101","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}